Close
New

Medscape is available in 5 Language Editions – Choose your Edition here.

 

Neurologic Complications of Organ Transplantation Treatment & Management

  • Author: Jasvinder Chawla, MD, MBA; Chief Editor: Stephen A Berman, MD, PhD, MBA  more...
 
Updated: Feb 09, 2015
 

Medical Care

Once the diagnosis is made, medical treatment of neurologic complications in transplant recipients is not significantly different from that in nontransplant patients. Nevertheless, complex drug interactions that may potentially compromise immunosuppression and allograft function must be considered.

  • Encephalopathy: Impairments of consciousness of variable etiology and severity, from mild confusion to coma, are not uncommon in transplant recipients. Establishing the cause determines further treatment, and delirious patients may also need symptomatic treatment (neuroleptics). In patients with toxic-metabolic encephalopathies, treatment is directed towards correcting the underlying cause while providing medical support (eg, respiratory support, parenteral feeding). In patients with hyponatremia, gradual correction is recommended.
  • Seizure
    • The underlying etiology of seizures and overall medical condition (including type of allograft and comorbidities) determine which antiepileptic drugs (AEDs) are used for treatment. Symptomatic seizures resulting from transient toxic and metabolic disturbances are treated by correcting the metabolic disturbance.
    • The most commonly used AED in transplant recipients is phenytoin because it is effective and simple to administer. Benzodiazepines (eg, lorazepam, diazepam) are useful in the acute management of seizures, whereas propofol is a third-line agent used for treatment of refractory status epilepticus. Phenobarbital is rarely used because of activation of liver enzymes, sedation, and long half-life, but it may be helpful in individual patients. Other medications used for treatment of refractory status epilepticus include midazolam and pentobarbital.
    • Levetiracetam should be considered for acute and maintenance treatment of seizures given the availability of
    • Valproic acid may be helpful in patients allergic to phenytoin or if phenytoin cannot be used because of drug interactions. Its use is avoided in children younger than 2 years and in liver transplant recipients because of potential hepatotoxicity. Use of carbamazepine and oxcarbazepine is limited by the lack of
    • Newer AEDs are mostly used as adjunctive agents, and the lack of significant drug interactions of topiramate, pregabalin and gabapentin makes them very attractive in transplant patients.
  • CNS infections
    • CNS infections carry high risk of morbidity and mortality. Because presenting signs and symptoms may be quite subtle in transplant recipients who are immunosuppressed, CNS infection should almost always be considered in the differential diagnosis. Depending on the clinical setting, therapy may be initiated with broad coverage (ie, antibiotic, antifungal, antiviral) or may be more focused. Delaying treatment may have catastrophic consequences.
    • Reversal of immunosuppression in the setting of effective antimicrobial therapy may precipitate immune reconstitution syndrome (IRS), which may manifest with neurologic complications (encephalomyelitis).[38]
  • Stroke and intracranial hemorrhage
    • The treatment of ischemic stroke in transplant recipients depends on the etiology and type of stroke (eg, cardioembolic, thrombotic, CNS infection, hypercoagulable state) as in nontransplant patients. Long-term control of cerebrovascular risk factors (eg, cholesterol, glucose control, hypertension, tobacco use) is needed as in nontransplant patients, particularly as improved protocols enable long-term survival. Some immunosuppressive medications (ie, sirolimus, cyclosporin) may worsen or trigger hyperlipidemia and hypertension.
    • Intracranial hemorrhage may be difficult to treat in transplant recipients, particularly if it is associated with coagulopathy, thrombocytopenia, or CNS infection.
    • Replacement of platelets and clotting factors (fresh frozen plasma) is needed in patients with thrombocytopenia and coagulopathy.
  • Neuromuscular disorders: Treatment of neuromuscular complications of transplantation is identical to that in nontransplant patients. Most common neuromuscular disorders in transplant recipients are perioperative neuropathies and critical illness myopathy/polyneuropathy (CIM/CIP). Treatment of patients with perioperative neuropathies and CIM/CIP is supportive with early initiation of physical therapy. Cautious use of paralytic agents and steroids in intensive care settings may decrease the occurrence of CIM. Patients with refractory myasthenia associated with chronic GVHD may benefit from rituximab.
Next

Surgical Care

See the list below:

  • Surgical removal of a cerebral hematoma in the acute stage, either by evacuation or aspiration, may be lifesaving.
  • Brain biopsy obtained by open or stereotactic technique is helpful in the evaluation of cranial masses of unknown origin, particularly if PTLD or brain tumors are suspected.
  • The decision to proceed with aspiration or open removal of a brain (or spinal cord) abscess is guided by the location, clinical course, and the degree of mass effect exerted by the abscess on the surrounding tissue. Stereotactic aspiration can be performed with deep abscesses.
  • Decompressive surgery is an emergency treatment of rapidly evolving hydrocephalus that is not responding to medical measures (ie, hyperventilation, mannitol).
  • Intraventricular placement of an Ommaya reservoir permits intrathecal treatment of fungal CNS infection.
Previous
Next

Consultations

A multidisciplinary approach is essential to the effective care of a transplant recipient. The transplant team has a central role in determining the level of immunosuppression. Various consultants play active roles in the care of these patients.

  • A neurologist is usually a consultant in the management of transplant patients, but may also admit the patient to neurology service.
  • Transplant team members have a central role in the treatment of transplant recipients. They coordinate with other teams and determine the required level of immunosuppression.
  • A critical care medicine specialist is particularly important in the early postoperative course.
  • An infectious disease specialist is invaluable in helping to evaluate possible opportunistic systemic and CNS infections.
  • Consulting a physical therapist is important because early initiation of physical therapy may accelerate recovery of transplant recipients.
  • Other medical and surgical specialists (including nephrologists, pulmonologists, cardiologists, neurosurgeons, and others) are also actively involved in the care of transplant recipients, depending on the type of allograft, comorbidities, and ongoing medical problems.
Previous
Next

Diet

Following transplantation, various dietary products may interfere with pharmacokinetics of immunosuppressive and other medications (eg, grapefruit juice).

  • Certain foods may increase risk of infection such as raw milk, soft cheeses, and hot dogs (Listeria monocytogenes).
  • Sodium restriction (2 g/d) may be helpful in management of cyclosporine-related hypertension.
  • Rapamycin and, to a lesser extent, cyclosporine are associated with hypercholesterolemia. Conversion from cyclosporine to tacrolimus may be helpful.
  • Use of statins in combination with cyclosporine may lead to rhabdomyolysis.
Previous
Next

Activity

No specific activity restrictions are necessary for patients with neurologic complications of transplantation.

Previous
 
 
Contributor Information and Disclosures
Author

Jasvinder Chawla, MD, MBA Chief of Neurology, Hines Veterans Affairs Hospital; Professor of Neurology, Loyola University Medical Center

Jasvinder Chawla, MD, MBA is a member of the following medical societies: American Academy of Neurology, American Association of Neuromuscular and Electrodiagnostic Medicine, American Clinical Neurophysiology Society, American Medical Association

Disclosure: Nothing to disclose.

Specialty Editor Board

Francisco Talavera, PharmD, PhD Adjunct Assistant Professor, University of Nebraska Medical Center College of Pharmacy; Editor-in-Chief, Medscape Drug Reference

Disclosure: Received salary from Medscape for employment. for: Medscape.

Howard S Kirshner, MD Professor of Neurology, Psychiatry and Hearing and Speech Sciences, Vice Chairman, Department of Neurology, Vanderbilt University School of Medicine; Director, Vanderbilt Stroke Center; Program Director, Stroke Service, Vanderbilt Stallworth Rehabilitation Hospital; Consulting Staff, Department of Neurology, Nashville Veterans Affairs Medical Center

Howard S Kirshner, MD is a member of the following medical societies: Alpha Omega Alpha, American Neurological Association, American Society of Neurorehabilitation, American Academy of Neurology, American Heart Association, American Medical Association, National Stroke Association, Phi Beta Kappa, Tennessee Medical Association

Disclosure: Nothing to disclose.

Chief Editor

Stephen A Berman, MD, PhD, MBA Professor of Neurology, University of Central Florida College of Medicine

Stephen A Berman, MD, PhD, MBA is a member of the following medical societies: Alpha Omega Alpha, American Academy of Neurology, Phi Beta Kappa

Disclosure: Nothing to disclose.

Additional Contributors

Norman C Reynolds, Jr, MD Neurologist, Veterans Affairs Medical Center of Milwaukee; Clinical Professor, Medical College of Wisconsin

Norman C Reynolds, Jr, MD is a member of the following medical societies: American Academy of Neurology, Association of Military Surgeons of the US, International Parkinson and Movement Disorder Society, Sigma Xi, Society for Neuroscience

Disclosure: Nothing to disclose.

Acknowledgements

Sasa Zivkovic, MD, PhD Associate Professor, Department of Neurology, Division of Neuromuscular Diseases, University of Pittsburgh and VA Pittsburgh Healthcare System

Sasa Zivkovic, MD, PhD is a member of the following medical societies: American Academy of Neurology, American Association of Neuromuscular and Electrodiagnostic Medicine, and Peripheral Nerve Society

Disclosure: Baxter Bioscience Meeting attendance expenses Attendee

References
  1. Organ Procurement and Transplantation Network (OPTN) and Scientific Registry of Transplant Recipients (SRTR). OPTN / SRTR 2010 Annual Data Report. Department of Health and Human Services, Health Resources and Services Administration, Healthcare Systems Bureau, Division of Transplantation; 2011. Available at http://www.srtr.org/annual_reports/2010/default.html. Accessed: May, 10, 2012.

  2. Zivkovic SA. Neurologic aspects of multiple organ transplantation. Handb Clin Neurol. 2014. 121:1305-17. [Medline].

  3. Patchell RA. Neurological complications of organ transplantation. Ann Neurol. 1994 Nov. 36(5):688-703. [Medline].

  4. Zivkovic S. Neuroimaging and neurologic complications after organ transplantation. J Neuroimaging. 2007 Apr. 17(2):110-23. [Medline].

  5. Zivkovic SA, Abdel-Hamid H. Neurologic manifestations of transplant complications. Neurol Clin. 2010 Feb. 28(1):235-51. [Medline].

  6. Neurologic complications in organ transplant recipients. Wijdicks EF, ed. Blue Books of Neurology. Oxford, England: Butterworth-Heinemann; 1999.

  7. Fishman JA, Rubin RH. Infection in organ-transplant recipients. N Engl J Med. 1998 Jun 11. 338(24):1741-51. [Medline].

  8. Fishman JA. Infections in immunocompromised hosts and organ transplant recipients: essentials. Liver Transpl. 2011 Nov. 17 Suppl 3:S34-7. [Medline].

  9. Singh N, Husain S. Infections of the central nervous system in transplant recipients. Transpl Infect Dis. 2000 Sep. 2(3):101-11. [Medline].

  10. Potluri K, Holt D, Hou S. Neurologic complications in renal transplantation. Handb Clin Neurol. 2014. 121:1245-55. [Medline].

  11. Zierer A, Melby SJ, Voeller RK, Guthrie TJ, Al-Dadah AS, Meyers BF, et al. Significance of neurologic complications in the modern era of cardiac transplantation. Ann Thorac Surg. 2007 May. 83(5):1684-90. [Medline].

  12. Heroux A, Pamboukian SV. Neurologic aspects of heart transplantation. Handb Clin Neurol. 2014. 121:1229-36. [Medline].

  13. Zivkovic SA, Jumaa M, Barisic N, McCurry K. Neurologic complications following lung transplantation. J Neurol Sci. 2009 May 15. 280(1-2):90-3. [Medline].

  14. Wong M, Mallory GB, Goldstein J, et al. Neurologic complications of pediatric lung transplantation. Neurology. 1999 Oct 22. 53(7):1542-9. [Medline].

  15. Shigemura N, Sclabassi RJ, Bhama JK, Gries CJ, Crespo MM, Johnson B, et al. Early major neurologic complications after lung transplantation: incidence, risk factors, and outcome. Transplantation. 2013 Mar 27. 95(6):866-71. [Medline].

  16. Wigfield CH, Love RB. Clinical neurology in lung transplantation. Handb Clin Neurol. 2014. 121:1237-43. [Medline].

  17. Jacewicz M, Marino CR. Neurologic complications of pancreas and small bowel transplantation. Handb Clin Neurol. 2014. 121:1277-93. [Medline].

  18. Jacewicz M, Marino CR. Neurologic complications of pancreas and small bowel transplantation. Handb Clin Neurol. 2014. 121:1277-93. [Medline].

  19. Zivkovic SA. Neurologic complications after liver transplantation. World J Hepatol. 2013 Aug 27. 5(8):409-16. [Medline]. [Full Text].

  20. Wijdicks EF, Hocker SE. Neurologic complications of liver transplantation. Handb Clin Neurol. 2014. 121:1257-66. [Medline].

  21. Zivkovic SA, Eidelman BH, Bond G, Costa G, Abu-Elmagd KM. The clinical spectrum of neurologic disorders after intestinal and multivisceral transplantation. Clin Transplant. 2010 Mar-Apr. 24(2):164-8. [Medline].

  22. Giraldo M, Martin D, Colangelo J, Bueno J, Reyes J, Fung JJ, et al. Intestinal transplantation for patients with short gut syndrome and hypercoagulable states. Transplant Proc. 2000 Sep. 32(6):1223-4. [Medline].

  23. Stracciari A, Guarino M. Neurologic complications of intestinal transplantation. Handb Clin Neurol. 2014. 121:1267-76. [Medline].

  24. Rodriguez TE. Neurologic complications of bone marrow transplantation. Handb Clin Neurol. 2014. 121:1295-304. [Medline].

  25. Rodriguez TE. Neurologic complications of bone marrow transplantation. Handb Clin Neurol. 2014. 121:1295-304. [Medline].

  26. Grauer O, Wolff D, Bertz H, Greinix H, Kühl JS, Lawitschka A, et al. Neurological manifestations of chronic graft-versus-host disease after allogeneic haematopoietic stem cell transplantation: report from the Consensus Conference on Clinical Practice in chronic graft-versus-host disease. Brain. 2010 Oct. 133(10):2852-65. [Medline].

  27. Delios AM, Rosenblum M, Jakubowski AA, DeAngelis LM. Central and peripheral nervous system immune mediated demyelinating disease after allogeneic hemopoietic stem cell transplantation for hematologic disease. J Neurooncol. 2012 Nov. 110(2):251-6. [Medline].

  28. Amato AA, Barohn RJ, Sahenk Z, Tutschka PJ, Mendell JR. Polyneuropathy complicating bone marrow and solid organ transplantation. Neurology. 1993 Aug. 43(8):1513-8. [Medline].

  29. Martín-Dávila P, Fortún J, López-Vélez R, Norman F, Montes de Oca M, Zamarrón P, et al. Transmission of tropical and geographically restricted infections during solid-organ transplantation. Clin Microbiol Rev. 2008 Jan. 21(1):60-96. [Medline].

  30. Srinivasan A, Burton EC, Kuehnert MJ. Transmission of rabies virus from an organ donor to four transplant recipients. N Engl J Med. 2005 Mar 17. 352(11):1103-11. [Medline].

  31. Schiff D, O'Neill B, Wijdicks E, Antin JH, Wen PY. Gliomas arising in organ transplant recipients: an unrecognized complication of transplantation?. Neurology. 2001 Oct 23. 57(8):1486-8. [Medline].

  32. Jacobson CA, LaCasce AS. Lymphoma: risk and response after solid organ transplant. Oncology (Williston Park). 2010 Sep. 24(10):936-44. [Medline].

  33. Campellone JV, Lacomis D, Kramer DJ, et al. Acute myopathy after liver transplantation. Neurology. 1998 Jan. 50(1):46-53. [Medline].

  34. Lacomis D. Neuromuscular disorders in critically ill patients: review and update. J Clin Neuromuscul Dis. 2011 Jun. 12(4):197-218. [Medline].

  35. Wijdicks EF, Litchy WJ, Wiesner RH, Krom RA. Neuromuscular complications associated with liver transplantation. Muscle Nerve. 1996 Jun. 19(6):696-700. [Medline].

  36. Dyck PJ, Velosa JA, Pach JM, et al. Increased weakness after pancreas and kidney transplantation. Transplantation. 2001 Oct 27. 72(8):1403-8. [Medline].

  37. Lichtenstein GR, Yang YX, Nunes FA, Lewis JD, Tuchman M, Tino G, et al. Fatal hyperammonemia after orthotopic lung transplantation. Ann Intern Med. 2000 Feb 15. 132(4):283-7. [Medline].

  38. Sun HY, Singh N. Opportunistic infection-associated immune reconstitution syndrome in transplant recipients. Clin Infect Dis. 2011 Jul 15. 53(2):168-76. [Medline].

  39. Bodkin CL, Eidelman BH. Sirolimus-induced posterior reversible encephalopathy. Neurology. 2007 Jun 5. 68(23):2039-40. [Medline].

  40. Bronster DJ, Emre S, Boccagni P, et al. Central nervous system complications in liver transplant recipients--incidence, timing, and long-term follow-up. Clin Transplant. 2000 Feb. 14(1):1-7. [Medline].

  41. Buis CI, Wiesner RH, Krom RA, et al. Acute confusional state following liver transplantation for alcoholic liver disease. Neurology. 2002 Aug 27. 59(4):601-5. [Medline].

  42. Chabolla DR, Wszolek ZK. Pharmacologic management of seizures in organ transplant. Neurology. 2006 Dec 26. 67(12 Suppl 4):S34-8. [Medline].

  43. Coplin WM, Cochran MS, Levine SR, Crawford SW. Stroke after bone marrow transplantation: frequency, aetiology and outcome. Brain. 2001 May. 124(Pt 5):1043-51. [Medline].

  44. Eidelman BH, Abu-Elmagd K, Wilson J, et al. Neurologic complications of FK 506. Transplant Proc. 1991 Dec. 23(6):3175-8. [Medline].

  45. Heroux A, Pamboukian SV. Neurologic aspects of heart transplantation. Handb Clin Neurol. 2014. 121:1229-36. [Medline].

  46. Kamar N, Bendall RP, Peron JM, Cintas P, Prudhomme L, Mansuy JM, et al. Hepatitis E virus and neurologic disorders. Emerg Infect Dis. 2011 Feb. 17(2):173-9. [Medline]. [Full Text].

  47. Kleinschmidt-DeMasters BK, Marder BA, Levi ME, et al. Naturally acquired West Nile virus encephalomyelitis in transplant recipients: clinical, laboratory, diagnostic, and neuropathological features. Arch Neurol. 2004 Aug. 61(8):1210-20. [Medline].

  48. Lewis MB, Howdle PD. Neurologic complications of liver transplantation in adults. Neurology. 2003 Nov 11. 61(9):1174-8. [Medline].

  49. Martinez AJ. The neuropathology of organ transplantation: comparison and contrast in 500 patients. Pathol Res Pract. 1998. 194(7):473-86. [Medline].

  50. Mendez O, Kanal E, Abu-Elmagd KM. Granulomatous amebic encephalitis in a multivisceral transplant recipient. Eur J Neurol. 2006 Mar. 13(3):292-5. [Medline].

  51. Penn I. Post-transplant malignancy: the role of immunosuppression. Drug Saf. 2000 Aug. 23(2):101-13. [Medline].

  52. Schwartz S, Ruhnke M, Ribaud P. Improved outcome in central nervous system aspergillosis, using voriconazoletreatment. Blood. 2005 Oct 15. 106(8):2641-5. [Medline].

  53. Sutcliffe RP, Maguire DD, Muiesan P, Dhawan A, Mieli-Vergani G, O'Grady JG. Liver transplantation for Wilson's disease: long-term results and quality-of-life assessment. Transplantation. 2003 Apr 15. 75(7):1003-6. [Medline].

  54. Wijdicks EF. Impaired consciousness after liver transplantation. Liver Transpl Surg. 1995 Sep. 1(5):329-34. [Medline].

  55. Wijdicks EF, Wiesner RH, Krom RA. Neurotoxicity in liver transplant recipients with cyclosporine immunosuppression. Neurology. 1995 Nov. 45(11):1962-4. [Medline].

  56. Zivkovic SA. Neurologic aspects of multiple organ transplantation. Handb Clin Neurol. 2014. 121:1305-17. [Medline].

Previous
Next
 
Neurotoxicity of calcineurin inhibitors manifests on MRI with predominantly posterior hyperintensities on T2-weighted and FLAIR imaging sequences (FLAIR; TE 175.0, TR 9002).
Muscle cryostat section at pH 4.6 shows decreased ATPase reactivity with reduced (arrows) and absent (asterisk) muscle fiber staining in critical illness myopathy (courtesy of Dr David Lacomis).
 
 
 
All material on this website is protected by copyright, Copyright © 1994-2016 by WebMD LLC. This website also contains material copyrighted by 3rd parties.